WEDNESDAY, March 20, 2019 — Postpartum depression is a common and often devastating condition for new mothers, but the U.S. Food and Drug Administration on Tuesday approved the first drug to help combat it. The drug, Zulresso (brexanolone), is delivered via intravenous infusion. “Postpartum depression is a serious condition that, when severe, can be life-threatening,” […]Continue Reading ...
The science of pharmacogenomics (PGx) studies how genetic variability affects an individual’s response to a drug. Most patients metabolize a medication as expected. But some eliminate it from the body before it can do its work, while others process it slowly, causing it to build up in the body and risk an overdose. Researchers in […]Continue Reading ...
When patients with HIV who are also battling opioid dependence go without addiction treatment, they are more likely to stop taking their HIV medications than drug-free patients. While the daily oral form of naltrexone–a drug that blunts the effects of opioids–is one option to treat opioid dependence, medication adherence among drug users is known to […]Continue Reading ...
The U.S. Food and Drug Administration today approved Zulresso (brexanolone) injection for intravenous (IV) use for the treatment of postpartum depression (PPD) in adult women. This is the first drug approved by the FDA specifically for PPD. “Postpartum depression is a serious condition that, when severe, can be life-threatening. Women may experience thoughts about harming […]Continue Reading ...
NEW HAVEN, Conn., Feb. 19, 2019 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) (“Biohaven”) announced today that it received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its product candidate verdiperstat (previously BHV-3241), a novel myeloperoxidase (MPO) inhibitor, for the treatment of multiple system atrophy (MSA). Verdiperstat is a […]Continue Reading ...
The Global Antibiotic Research and Development Partnership (GARDP) and Evotec AG are today announcing the formation of a new strategic public-private partnership to tackle the growing threat of antimicrobial resistance (AMR). By joining forces, Evotec and GARDP will leverage their capabilities and networks to address drug-resistant bacterial infections. This includes bringing together GARDP’s clinical expertise […]Continue Reading ...
WEDNESDAY, March 13, 2019 — The U.S. Food and Drug Administration on Tuesday approved a new generic version of the high blood pressure/heart failure drug valsartan, saying the move might help ease the current medication shortage. The agency said it prioritized review of the drug from Alkem Laboratories Ltd. after multiple recalls of other generic […]Continue Reading ...
Patients with HER2-positive breast cancer face something of a predicament: The most effective drug to treat the cancer is also the most toxic. Trastuzumab, sold under the brand name Herceptin, causes cardiac problems in about 15 percent of patients who take it. The chemotherapy drug causes their hearts to contract less vigorously, decreasing blood flow […]Continue Reading ...
Approximately 1 in 9 women in the United States experiences symptoms of postpartum depression, according to the Centers for Disease Control and Prevention. Now, the Food and Drug Administration (FDA) has approved brexanolone, an analog of the endogenous human hormone allopregnanolone and the first drug specifically designed to treat postpartum depression. Some psychiatric drugs owe […]Continue Reading ...
The prognosis for older patients with acute myeloid leukemia (AML) is poor: very few achieve remission and for those that don’t the option is largely palliative. Every year almost 1000 Australians die of the disease and clinical trials into new therapies for older patients have largely failed. A new Australian drug trial has achieved a […]Continue Reading ...
“The major thing is, of course, the rapid effect,” said Dr. Margaret Spinelli, a clinical professor of psychiatry at Columbia University.Continue Reading ...
FDA Approves Zulresso (brexanolone) for the Treatment of Post-Partum Depression March 19, 2019 — The U.S. Food and Drug Administration today approved Zulresso (brexanolone) injection for intravenous (IV) use for the treatment of postpartum depression (PPD) in adult women. This is the first drug approved by the FDA specifically for PPD. “Postpartum depression is a serious […]Continue Reading ...
The advances in Artificial intelligence (AI) have successfully propagated into the many areas such as computer vision, speech recognition, and natural language processing. AI is now rapidly propagating into the areas requiring substantial domain expertise such as biology, chemistry promising to speed up, improving the success rates, and lower the cost of drug discovery and […]Continue Reading ...
In a paper to be published in the forthcoming issue in NANO, researchers from Zhejiang have uncovered a novel method of using nanocarrier-based biological fluorescent probes for detecting amphetamine and ketamine in latent fingermark, in a bid to combat drug abuse. This method has the potential to be extended to other drugs and molecules. Drug […]Continue Reading ...
A new study from researchers at Columbia University Vagelos College of Physicians and Surgeons shows that a drug given to some pregnant women to prevent severe respiratory ailments in preterm newborns reduces healthcare costs. Drug previously shown effective in reducing breathing ailments in preemies Approximately 7 percent of babies in the U.S. are born in […]Continue Reading ...
- Combined immunosuppression may be effective, safe in treating older patients with Crohn’s disease
- GSK sells health drinks arm, buys US cancer treatment firm
- Bacteria and innate immune factors in birth canal, cervix may be key to predicting preterm births
- IgG antibodies play unexpected role in atherosclerosis
- Sounds and vibrations are quite similar for the brain, finds new study
- Practices for Reducing COPD Hospital Readmissions Explored
- Could an eye doctor diagnose Alzheimer’s before you have symptoms?
- Enzyme inhibitor stops inflammation and neurodevelopmental disorders in mouse models
- Walk, Dance, Clean: Even a Little Activity Helps You Live Longer
- Americans used less eye care in 2014 versus 2008
- Study finds link between depression in 20s linked to memory loss in 50s
- New tool helps physiotherapy students to master complex fine motor skills
- The AMR Centre secures £2.3m funding boost
- Study examines effects of taking ondansetron during first trimester of pregnancy
- Researchers identify a more effective treatment for cancer
- Open-source solution for multiparametric optical mapping of the heart’s electrical activity
- New nanotechnology approach shows promise in treating triple negative breast cancer
- Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain
- Maternal deaths following C-section 50 times higher in Africa compared to high-income countries
- Apple watch could detect irregular heart beat says study